Modulating co-stimulation: a rational strategy in the treatment of rheumatoid arthritis?

Rheumatoid arthritis (RA) is a common destructive inflammatory disease that affects 0.5–1% of the population in many countries. Even though several new treatments have been introduced for patients with RA, a considerable proportion of patients do not benefit from these, and the need for alternative...

Descripción completa

Detalles Bibliográficos
Autores principales: Malmström, Vivianne, Trollmo, Christina, Klareskog, Lars
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833979/
https://www.ncbi.nlm.nih.gov/pubmed/15833144
http://dx.doi.org/10.1186/ar1505
Descripción
Sumario:Rheumatoid arthritis (RA) is a common destructive inflammatory disease that affects 0.5–1% of the population in many countries. Even though several new treatments have been introduced for patients with RA, a considerable proportion of patients do not benefit from these, and the need for alternative treatment strategies is clear. This review explores the potential for a therapy targeting the adaptive immune system by modulating co-stimulation of T cells with a CTLA4–Ig fusion protein (abatacept).

Ejemplares similares